WARNING: Life-threatening allergic reactions have occurred in some patients during VIMIZIM® (elosulfase alfa) infusions and up to 3 hours after infusion. Patients with acute respiratory illness may be at increased risk and require additional monitoring.

VIMIZIM significantly improves endurance as demonstrated by improved performance on the 6MWT (P=0.0174)1

VIMIZIM efficacy summary

  • MOR-004—a randomized, double-blind, placebo-controlled, phase 3 clinical trial involving 176 patients with Morquio A—is the largest interventional trial to evaluate the efficacy and safety of enzyme replacement therapy (ERT) in any mucopolysaccharidosis (MPS) disease to date1,3 
  • VIMIZIM® (elosulfase alfa) 2 mg/kg/wk significantly improves endurance, as demonstrated by improved performance on the 6MWT (P=0.0174)1 
  • Improvement in endurance seen with VIMIZIM can be related to improvement in activities of daily living, such as walking or time away from a wheelchair1 

Primary endpoint: 6MWT/statistically significant improvement

Improvement in the 6MWT reflects a change in disease progression5,10

Morquio A Syndrome patients on VIMIZIM demonstrated a 22.5 meteR improvement in the 6 minute walk test
  • In the VIMIZIM® (elosulfase alfa) 2 mg/kg/wk group:
  • Patients in the VIMIZIM once-weekly treatment arm walked further at week 24 than at baseline in the 6MWT with a mean 23.9% improvement3
  • Over 50% of patients in the once-weekly treatment arm had a >20-meter improvement, and approximately 15% had a >100-meter improvement3
  • The congenital effects of Morquio A lead to intrinsically reduced endurance as compared to the unaffected population; therefore, in patients with Morquio A, even small changes in distance on the 6MWT can be clinically significant10

At 24 weeks, patients taking VIMIZIM walked farther than patients on placebo3


In a cumulative distribution function analysis of the 6MWT change from baseline to Week 24, patients in the weekly treatment arm showed clear separation from placebo across all levels of response.

Study designs for MOR-004 and MOR-0051,3



All results presented are for the intent-to-treat (ITT) population (all subjects randomized to study treatment who received at least 1 dose of study drug). Utilization of the ITT population is a widely accepted practice in the analysis of clinical trials and is designed to avoid misleading data that can arise in intervention research, such as nonrandom attrition of participants from the study.

6-minute walk test (6MWT)
In the efficacy analysis, improvements in patients’ endurance were assessed by the 6MWT1
Morquio A Natural history study
The MorCAP study demonstrates a progressive decline in endurance in patients with Morquio A4
VIMIZIM safety
VIMIZIM safety has been demonstrated in the largest interventional trial of enzyme replacement therapy (ERT) in any mucopolysaccharidosis (MPS) disease1,3

Important Safety Information

Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM® (elosulfase alfa) infusions. Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria have been reported to occur during VIMIZIM infusions, regardless of duration of the course of treatment. Closely observe patients during and after VIMIZIM administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

Due to the potential for anaphylaxis, appropriate medical support should be readily available when VIMIZIM is administered and for an appropriate period of time following administration. In clinical trials, cases of anaphylaxis occurred as early as 30 minutes from the start of infusion and up to three hours after infusion, and as late into treatment as the 47th infusion.

In clinical trials, hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion. Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.

Because of the potential for hypersensitivity reactions, administer antihistamines with or without antipyretics prior to infusion. Management of hypersensitivity reactions should be based on the severity of the reaction and include slowing or temporary interruption of the infusion and/or administration of additional antihistamines, antipyretics, and/or corticosteroids for mild reactions. However, if severe hypersensitivity reactions occur, immediately stop the infusion of VIMIZIM and initiate appropriate treatment.

Consider the risks and benefits of re-administering VIMIZIM following a severe reaction.

Patients with acute febrile or respiratory illness at the time of VIMIZIM infusion may be at higher risk of life-threatening complications from hypersensitivity reactions. Careful consideration should be given to the patient’s clinical status prior to administration of VIMIZIM and consider delaying the VIMIZIM infusion.

Sleep apnea is common in MPS IVA patients. Evaluation of airway patency should be considered prior to initiation of treatment with VIMIZIM. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an acute reaction, or extreme drowsiness/sleep induced by antihistamine use.

Spinal or cervical cord compression (SCC) is a known and serious complication of MPS IVA and may occur as part of the natural history of the disease. In clinical trials, SCC was observed both in patients receiving VIMIZIM and patients receiving placebo. Patients with MPS IVA should be monitored for signs and symptoms of SCC (including back pain, paralysis of limbs below the level of compression, urinary and fecal incontinence) and given appropriate clinical care.

All patients treated with VIMIZIM 2 mg/kg once per week in the placebo-controlled trial developed anti-drug antibodies. The relationship between the presence of neutralizing antibodies and long-term therapeutic response or occurrence of anaphylaxis or other hypersensitivity reactions could not be determined.

VIMIZIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if VIMIZIM is present in human milk. Exercise caution when administering VIMIZIM to a nursing mother. There is a Morquio A Registry that collects data on pregnant women and nursing mothers with MPS IVA who are treated with VIMIZIM. Contact for information and enrollment.

Safety and effectiveness in pediatric patients below 5 years of age have not been established and are currently being evaluated. In clinical trials, the most common adverse reactions (≥10%) occurring during infusion included pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue. The acute reactions requiring intervention were managed by either temporarily interrupting or discontinuing infusion, and administering additional antihistamine, antipyretics, or corticosteroids.

To report SUSPECTED ADVERSE REACTIONS contact BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to


BioMarin Pharmaceutical Inc.

Novato, CA 94949

BioMarin Medical Information: 1-800-983-4587

To report suspected adverse events email

BioMarin RareConnections™: 1-866-906-6100